(Reuters) – The U.S. Food and Drug Administration’s (FDA) staff reviewers said on Monday that updated COVID-19 vaccines should target subvariants of the XBB variant for the 2023-204 vaccination campaign.
The COVID vaccination campaign should feature a monovalent vaccine targeting either the XBB.1.5, XBB.1.16, or XBB.2.3, the staff reviewers said ahead of a meeting of the FDA’s panel of independent experts on Thursday.
(Reporting by Manas Mishra in Bengaluru)
